The global shift toward personalized medicine has placed Oligonucleotide APIs at the forefront of pharmaceutical development. In Granada, as the research landscape pivots toward chronic disease management and rare genetic disorders, the demand for high-purity, cGMP-compliant API suppliers is critical. Leveraging China’s mature manufacturing infrastructure, we provide the supply chain resilience required for local R&D institutions and commercial entities in Granada to scale from clinical trials to market access.
Oligonucleotide therapy represents the "third wave" of drug development. Our roadmap integrates automated synthesis and rigorous purification technologies (HPLC/MS) to ensure 99%+ purity. We are currently investing in green chemistry to minimize waste, aligning with European and International compliance standards, ensuring our partners in Granada are future-proofed against evolving regulatory demands.
By bypassing traditional logistical bottlenecks, our direct-to-market supply strategy ensures that Granada’s biotech pioneers receive batch-consistent APIs. Our quality management systems are designed for traceability, offering comprehensive CoA, MSDS, and DMF support, which significantly reduces the time-to-market for innovative therapies.
Our APIs meet all international pharmacopoeia standards.
Optimized logistics ensure rapid transit from China to Granada.
We support small-batch R&D to large-scale commercial API supply.
